Cite
HARVARD Citation
Becnel, M. et al. (2019). Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial. British journal of haematology. pp. 874-882. [Online].